NCT05126433 - Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions

Advanced Solid TumorMetastatic Solid TumorUrothelial CancerPoorly Differentiated Neuroendocrine CarcinomasHomologous Recombination Deficient-Positive Malignancies Agnostic

Interventions

DRUG

Lurbinectedin

Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)

Trial Locations (17)

10029

Icahn School of Medicine at Mount Sinai, New York

15232

UPMC Hillman Cancer Center Investigational Drug Service, Pittsburgh

19104

University of Pennsylvania, Philadelphia

22031

Inova Schar Cancer Institute, Fairfax

28203

Levine Cancer Institute, Charlotte

29607

Bon Secours Hematology and Oncology, Greenville

33612

Moffitt Cancer Center, Tampa

33705

Sarah Cannon, Florida Cancer Specialist, St. Petersburg

33901

Florida Cancer Specialists, Fort Myers

37203

Sarah Cannon, Tennesse Oncology, Nashville

41501

Pikeville Medical Center, Pikeville

43219

Sarah Cannon, Zangmeister Cancer Center, Columbus

68124

Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha

77030

MD Anderson, Houston

94305

Stanford Cancer Center, Stanford

06360

Eastern Connecticut Hematology and Oncology, Norwich

02215

Dana Farber, Boston